Cargando…

Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer

IMPORTANCE: The BEACON trial showed that combination therapy with encorafenib (BRAF inhibitor) and cetuximab (EGFR inhibitor) was associated with prolonged overall survival compared with standard chemotherapy in patients with metastatic BRAF variant colorectal cancer. However, the cost-effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Kishan K., Stein, Stacey, Lacy, Jill, O’Hara, Mark, Huntington, Scott F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804917/ https://www.ncbi.nlm.nih.gov/pubmed/33433598 http://dx.doi.org/10.1001/jamanetworkopen.2020.33441

Ejemplares similares

Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy
por: Corsini, Christian, et al.
Publicado: (2023)

Metastatic Pancreatic Cancer with BRAF and P53 Mutations: Case Report of Therapeutic Response to Doublet Targeted Therapy
por: Sasankan, Shenthol, et al.
Publicado: (2020)

Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma
por: Cai, Chao, et al.
Publicado: (2021)

Association of BRAF Variants With Disease Characteristics, Prognosis, and Targeted Therapy Response in Intrahepatic Cholangiocarcinoma
por: Xin, Hao-Yang, et al.
Publicado: (2023)

Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
por: Parisi, Alessandro, et al.
Publicado: (2021)

On the $ doublet in $
por: Astner, G, et al.
Publicado: (1970)

Protocol for Identification and Removal of Doublets with DoubletDecon
por: DePasquale, Erica A.K., et al.
Publicado: (2020)

Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy
por: Mazor, Roei D, et al.
Publicado: (2020)

Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
por: Curl, Patti, et al.
Publicado: (2014)

BRAF-mutated metastatic colorectal cancer between past and future
por: Cremolini, Chiara, et al.
Publicado: (2015)

The Role of BRAF in Metastatic Colorectal Carcinoma–Past, Present, and Future
por: Djanani, Angela, et al.
Publicado: (2020)

Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
por: Grassi, Elisa, et al.
Publicado: (2021)

BRAF Non-V600 Mutations in Metastatic Colorectal Cancer
por: Liu, Junjia, et al.
Publicado: (2023)

BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy
por: Li, Zi-Nan, et al.
Publicado: (2020)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

Correction: Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
por: Curl, Patti, et al.
Publicado: (2015)

Receipt of Targeted Therapy and Survival Outcomes in Patients With Metastatic Colorectal Cancer
por: Koroukian, Siran M., et al.
Publicado: (2023)

BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in BRAF-Mutated Metastatic Colorectal Cancer—A Case Series Study Target Therapy of BRAF-Mutated mCRC
por: Yeh, Jen-Hao, et al.
Publicado: (2021)

Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer
por: Ntavatzikos, Anastasios, et al.
Publicado: (2017)

The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer
por: Fanelli, Giuseppe Nicolò, et al.
Publicado: (2020)

Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients
por: Rosati, Gerardo, et al.
Publicado: (2021)

The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response
por: Pinto, Rosamaria, et al.
Publicado: (2016)

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF(V600E) metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2022)

doubletD: detecting doublets in single-cell DNA sequencing data
por: Weber, Leah L, et al.
Publicado: (2021)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
por: Xu, Ting, et al.
Publicado: (2022)

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
por: Kopetz, Scott, et al.
Publicado: (2015)

Uncoupling of Genomic and Epigenetic Signals in the Maintenance and Inheritance of Heterochromatin Domains in Fission Yeast
por: Wheeler, Bayly S., et al.
Publicado: (2012)

Facilitation of Definitive Cancer Diagnosis With Quantitative Molecular Assays of BRAF V600E and TERT Promoter Variants in Patients With Thyroid Nodules
por: Fu, Guodong, et al.
Publicado: (2023)

Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2016)

BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options
por: Hummel, Michael, et al.
Publicado: (2021)

Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives
por: Ottaiano, Alessandro, et al.
Publicado: (2022)

Real‐world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer
por: Xu, Ting, et al.
Publicado: (2023)

BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature
por: Guerrero, Patricia, et al.
Publicado: (2023)

Advances in doublet mechanics
por: Ferrari, Mauro, et al.
Publicado: (1997)

Doublet final focus
por: Autin, Bruno
Publicado: (1996)

The inert doublet model
por: Arias, C, et al.
Publicado: (2010)

Doublet final focus
por: Autin, B
Publicado: (1996)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

DoubletDecon: Deconvoluting Doublets from Single-Cell RNA-Sequencing Data
por: DePasquale, Erica A.K., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tgj28p0r3956lkq2pee5fm7v4r